Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11830858 | 0.91 | CA2 (0.54) | NPC1RAB9ACTBP2L3MBTL1LMNA | |
| SCHEMBL4194796 | 0.89 | CA2 (0.46) | NPC1RAB9ACTBP2L3MBTL1LMNA | |
| SCHEMBL7628204 | 0.88 | LTA4H (0.54) | NPC1RAB9ACTBP2KMT2ACNR2 | |
| SCHEMBL14160462 | 0.83 | NPC1 (0.52) | NPC1RAB9ACTBP2L3MBTL1LMNA | |
| SCHEMBL28455325 | 0.82 | LMNA (0.54) | LMNAMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL1479915 | 0.82 | NPC1 (0.55) | NPC1RAB9ACTBP2L3MBTL1LMNA | |
| SCHEMBL75665 | 0.80 | CA2 (0.62) | NPC1RAB9ACTBP2L3MBTL1LMNA | |
| SCHEMBL11510399 | 0.80 | CA2 (0.52) | NPC1RAB9ACTBP2L3MBTL1LMNA | |
| SCHEMBL6399879 | 0.80 | NPC1 (0.53) | NPC1RAB9ACTBP2L3MBTL1LMNA | |
| SCHEMBL5445821 | 0.80 | CA2 (0.62) | NPC1RAB9ACTBP2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190350903-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2019-11-21 | — | — | US | claimed |
| EP-3078374-B1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | UNIV VANDERBILT (US) | 2019-06-19 | — | — | EP | claimed |
| EP-3078374-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | Vanderbilt University (US) | 2016-10-12 | — | — | EP | claimed |
| US-20140371261-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-12-18 | — | — | US | claimed |
| EP-2768499-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | Vanderbilt University (US) | 2014-08-27 | — | — | EP | claimed |
| WO-2013059245-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2013-04-25 | — | — | WO | claimed |
| EP-1556417-B1 | RACEMOSELECTIVE PREPARATION OF BRIDGED METALLOCENE COMPLEXES HAVING UNSUBSTITUTED OR 2-SUBSTITUTED INDENYL LIGANDS | BASELL POLYOLEFINE GMBH (DE) | 2009-06-10 | — | — | EP | claimed |
| US-7358381-B2 | Racemoselective preparation of bridged metallocene complexes having unsubstituted or 2-substituted indenyl ligands | BASELL POLYOLEFINE GMBH (DE) | 2008-04-15 | — | — | US | claimed |
| EP-1554297-B1 | RACEMOSELECTIVE SYNTHESIS OF RAC-DIORGANOSILYLBIS(2-METHYLBENZO¬E|INDEYL) ZIRCONIUM COMPONDS | BASELL POLYOLEFINE GMBH (DE) | 2006-07-12 | — | — | EP | claimed |
| US-20060111527-A1 | Racemoselective preparation of bridged metallocene complexes having unsubstituted or 2-substituted indenyl ligands | EQUISTAR CHEMICALS, LP | 2006-05-25 | — | — | US | claimed |
| CN-1703418-A | Racemoselective synthesis of rac-diorganosilylbis (2-methylbenzo [ e ] indenyl) zirconium compounds | BASELL POLYOLEFINE GMBH (DE) | 2005-11-30 | — | — | CN | claimed |
| EP-1554297-A1 | RACEMOSELECTIVE SYNTHESIS OF RAC-DIORGANOSILYLBIS(2-METHYLBENZO[E]INDEYL) ZIRCONIUM COMPONDS | Basell Polyolefine GmbH (DE) | 2005-07-20 | — | — | EP | claimed |
| WO-2004037840-A1 | RACEMOSELECTIVE SYNTHESIS OF RAC-DIORGANOSILYLBIS(2-METHYLBENZO[E]INDEYL) ZIRCONIUM COMPONDS | BASELL POLYOLEFINE GMBH (DE) | 2004-05-06 | — | — | WO | claimed |
| US-4481369-A | VIA TRICARBONYL(TRIPHENYLPOSPHINE) COBALTATE | ETHYL CORPORATION (US) | 1984-11-06 | — | — | US | claimed |
| US-4481368-A | Process for preparing α-keto-carboxylic acids from acyl halides | ETHYL CORPORATION (US) | 1984-11-06 | — | — | US | claimed |
| EP-4676923-A1 | BIARYLAMIDE DERIVATIVES AND THEIR USE AS PKMYT1 INHIBITORS | Cancer Research Technology Limited (GB) | 2026-01-14 | — | — | EP | disclosed |
| US-20250388592-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | REMYND N.V. (BE) | 2025-12-25 | — | — | US | disclosed |
| US-3976653-A | ANALGESIC ANTAGONIST | STERLING DRUG INC. (US) | 1976-08-24 | — | — | US | disclosed |
| US-3965105-A | ANTIINFLAMMATORY | STERLING DRUG INC. (US) | 1976-06-22 | — | — | US | disclosed |
| US-3953465-A | ATHEROSCLEROSIS | MERCK & CO., INC. (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190350903-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | NPC1 2923/4885RAB9A 4880/4885CTBP2 3209/4885 |
| US-20060111527-A1 | Racemoselective preparation of bridged metallocene complexes having unsubstituted or 2-substituted indenyl ligands | ITPA, IMPA1, INTS9 | NPC1 3012/4885RAB9A 2490/4885CTBP2 1074/4885 |
| US-20140371261-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | NPC1 2767/4885RAB9A 4882/4885CTBP2 3477/4885 |
| US-20250388592-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | SNCA, CHRNA6, CHRNA5 | NPC1 69/4885RAB9A 306/4885CTBP2 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.